You are here: Home » Companies » News
Business Standard

Zydus Cadila gets final US FDA nod to market arthritis drugs

It will manufacture the drug at the Moraiya facility in Ahmedabad

Press Trust of India  |  New Delhi 

Zydus Cadilla, healthcare, Sentynl, Ahmedabad
Zydus Cadila

Drug firm today said it has received final approval from the US health regulator to market indomethacin extended release capsules used in treating painful and inflammatory conditions such as arthritis.

The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 75 mg, it said in a filing.

It will manufacture the drug at the Moraiya facility in Ahmedabad.

said it has more than 155 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.

Shares of the company's listed entity were trading 2.70 per cent down at Rs 461.50 per scrip on

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Wed, September 27 2017. 13:03 IST